

Palla Pharma Limited

(formerly TPI Enterprises Limited)

ASX Announcement

14. June 2019

Change of Company Name and ASX Code

At the Company's 2019 Annual General Meeting, held on Thursday 30 May 2019, shareholders formally approved the change of company name to Palla Pharma Limited. The name change is one component of a new brand identity that reflects the Company's shift of its operations, product range and culture to that of a global pharmaceutical business.

We now confirm that the change of Company name from TPI Enterprises Limited to Palla Pharma Limited has been processed by the Australian Securities and Investments Commission. The effective date for the change to the Company's ASX listing details will be Wednesday 19 June 2019, when the ASX Listing Code will change from "TPE" to "PAL".

A rebranding project is currently being implemented and the Company will make a further ASX announcement regarding changes to communication details, including an updated website, in due course.

For more information please contact:

Jarrold Ritchie
Managing Director/CEO
Palla Pharma Limited
+613 9301 0800

Brendan Middleton
Chief Financial Officer
Pall Pharma Limited
+613 9301 0800

About Palla Pharma Limited

Palla Pharma Limited is one of three licensed poppy processors in Australia, and the only Australian-owned company. It is one of only three companies globally that is vertically integrated from poppy growing through to tableting production. Palla Pharma has developed an innovative, efficient and environmentally-sustainable extraction and purification manufacturing process which allows the company to deliver a highly competitive pricing platform. The Company's strategy is to secure access to regulated downstream narcotics markets to leverage its reliable, cost-competitive upstream raw material capability.